Skip to main content

SYSTEMATIC REVIEW article

Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1487501

Literature review analysis of aortitis induced by granulocyte-colony stimulating factor

Provisionally accepted
Ting Zhao Ting Zhao Huanhuan Xu Huanhuan Xu *
  • Weifang People's Hospital, Weifang, China

The final, formatted version of the article will be published soon.

    Background: Recombinant human granulocyte-colony stimulating factors (G-CSF)-induced aortitis is a rare but particularly serious adverse event, commonly seen in cancer patients undergoing chemotherapy. The aim of this article is to clarify the clinical characteristics of G-CSF-induced aortitis and provide effective references for clinical diagnosis and intervention.Methods: Case reports of adverse reactions of aortitis induced by G-CSF were collected from the relevant databases. The patients' basic information and adverse reaction process were recorded and subjected to descriptive analysis.Results: A total of 72 patients were enrolled, including 14 males and 58 females, with a mean age of 61.83 ± 10.30 years. The G-CSF type with the highest frequency of occurrence of aortitis is pegfilgrastim. Apart from three healthy stem cell donors, G-CSF-induced aortitis was primarily found in patients with underlying malignancies, especially in patients with breast cancer. The most common anticancer drugs used at onset were docetaxel, cyclophosphamide, and doxorubicin. CT scan showed that aortitis most commonly occured in the aortic arch and its branches. Most patients had a good prognosis, but 3 cases developed complications. Importantly, G-CSF-induced aortitis was also found in 4 asymptomatic patients.Conclusion: This article found that G-CSF-induced aortitis not only occured in cancer patients undergoing chemotherapy as previously reported in literature, but also in healthy stem cell donors. Especially, asymptomatic patients with G-CSF-induced aortitis faced a greater risk of being missed by the attending physician.

    Keywords: Recombinant human granulocyte-colony stimulating factor1, Aortitis 2, Adverse event 3, Cancer 4, chemotherapy 5

    Received: 28 Aug 2024; Accepted: 04 Dec 2024.

    Copyright: © 2024 Zhao and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Huanhuan Xu, Weifang People's Hospital, Weifang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.